Teva Sues FDA For Excluding Copaxone From BLA Transition; Wants To Use Biosimilar Litigation Process

 
• By Brenda Sandburg
Medical needles of Copaxone
Teva Wants Copaxone To Be Deemed A Biologic

More from Biosimilars

More from Biosimilars & Generics